
TSE:BNS
This summary was created by AI, based on 30 opinions in the last 12 months.
The Bank of Nova Scotia (BNS) has elicited mixed reviews from experts. Some highlight its strong positioning for future growth due to investments in GenAI and a favorable regulatory environment that allows for increased lending capacity. However, others express concerns about BNS's performance relative to its Canadian peers, noting it as the weakest among them despite a decent dividend yield of around 4.5% and recent strategic moves to invest in the U.S. market through KEY. While some analysts see potential for long-term gains, particularly with the new CEO at the helm, others urge caution citing stagnant loan growth and rising provisions for credit losses (PCLs). The overall sentiment reflects a blend of optimism for its turnaround and skepticism about its ability to catch up to its competitors amidst ongoing economic challenges.
Two completely different sectors. First questions are what's already in your portfolio and at what weighting? Similar dividend yields and similarly disappointing to investors in 2022. BNS has had poor performance for quite some time, and now a leadership change. TRP has a good, strong management team, but cost overruns. At these levels, he prefers TRP -- underlying business doing quite well, core fundamentals extremely strong, project issues will get solved though investors may have to wait a bit.
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Better than expected quarter reported. Loss provisions declined. Trading back in line with peers. Unlock Premium - Try 5i Free
We again reiterate this large Canadian chartered bank as a TOP PICK. Recent earnings missed analyst expectations due to rising capitalization requirements. We have confidence with their strategy going forward as they are still demonstrating growth in cash reserves while retiring debt and buying back shares. We continue to recommend a stop loss at $63.00, looking to achieve $78.50 — upside potential over 15%. Yield 5.6%
(Analysts’ price target is $78.33)